A comparison of the safety, feasibility, and tolerability of ECT and ketamine for treatment-resistant depression

References

• Evans-Lacko S, Aguilar-Gaxiola S, Al-Hamzawi A, et al. Socio-economic variations in the mental health treatment gap for people with anxiety, mood, and substance use disorders: results from the who world mental health (wmh) surveys. Psychol Med. 2018;48(9):1560–1571. DOI:10.1017/S0033291717003336.
   PubMed Web of Science ®Google Scholar
• (GHDx) IoHMaEGHDE. 2021 [cited 2021 October 31]. Available from: http://ghdx.healthdata.org/gbd-results-tool?params=gbd-api-2019-permalink/d780dffbe8a381b25e1416884959e88b
   Google Scholar
• Gaynes BN, Lux L, Gartlehner G, et al. Defining treatment‐resistant depression. Depress Anxiety. 2020;37(2):134–145. DOI:10.1002/da.22968.
   PubMed Web of Science ®Google Scholar
• Thase ME, Schwartz TL. Choosing medications for treatment-resistant depression based on mechanism of action. J Clin Psychiatry. 2015;76(6).
   Web of Science ®Google Scholar
• Akil H, Gordon J, Hen R, et al. Treatment resistant depression: a multi-scale, systems biology approach. Neurosci Biobehav Rev. 2018;84:272–288.
   PubMed Web of Science ®Google Scholar
• Thomas L, Kessler D, Campbell J, et al. Prevalence of treatment-resistant depression in primary care: cross-sectional data. Br J Gen Pract. 2013;63(617):e852–e858. DOI:10.3399/bjgp13X675430.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a star* d report. Am J Psychiatry. 2006;163(11):1905–1917. DOI:10.1176/ajp.2006.163.11.1905.
   PubMed Web of Science ®Google Scholar
• Fekadu A, Wooderson SC, Markopoulo K, et al. What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies. J Affect Disord. 2009;116(1–2):4–11. DOI:10.1016/j.jad.2008.10.014.
   PubMed Web of Science ®Google Scholar
• Li G, Fife D, Wang G, et al. All-cause mortality in patients with treatment-resistant depression: a cohort study in the us population. Ann Gen Psychiatry. 2019;18(1):1–8. DOI:10.1186/s12991-019-0248-0.
   PubMed Web of Science ®Google Scholar
• Goldberg JF. Electroconvulsive therapy: still the gold standard for highly treatment-resistant mood disorders. CNS Spectr. 2021;1–2. DOI:10.1017/S1092852921000110
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (UK). Depression in adults: treatment and management. 2021. Available from: https://www.nice.org.uk/guidance/gid-cgwave0725/documents/short-version-of-draft-guideline-2
   Google Scholar
• Patten SB. Updated canmat guidelines for treatment of major depressive disorder. Los Angeles (CA): SAGE Publications Sage; 2016. **Canadian Network for Mood and Anxiety Disorder Treatment guidelines for treating MDD.
   Google Scholar
• Mayer-Gross W, Slater E, Roth M. Clinical psychiatry. Baltimore: Williams and Wilkins Company; 1960.
   Google Scholar
• Moncrieff J. The creation of the concept of an antidepressant: an historical analysis. Soc sci med. 2008;66(11):2346–2355.
   PubMed Web of Science ®Google Scholar
• Association AP The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging (a task force report of the American psychiatric association). 2008.* APA task force guidelines for ECT practice
   Google Scholar
• Wilkinson ST, Agbese E, Leslie DL, et al. Identifying recipients of electroconvulsive therapy: data from privately insured americans. Psychiatr Serv. 2018;69(5):542–548. DOI:10.1176/appi.ps.201700364.
   PubMed Web of Science ®Google Scholar
• Kasper S, Cubała WJ, Fagiolini A, et al. Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: basic science, evidence-based knowledge and expert guidance. World J Biol Psychiatry. 22(6): 468–482. 2021. 10.1080/15622975.2020.1836399.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Yang C. Is (s)-norketamine an alternative antidepressant for esketamine? Eur Arch Psychiatry Clin Neurosci. 2019;269(7):867–868.
   PubMed Web of Science ®Google Scholar
• Iqbal SZ, Mathew SJ. Ketamine for depression clinical issues. In: Advances in pharmacology. Vol. 89. London, United Kingdom: Elsevier; 2020. p. 131–162.
   Google Scholar
• Chang LC, Rajagopalan S, Mathew SJ. The history of ketamine use and its clinical indications. In: Mathew SJ, Zarate C, editors. Ketamine for treatment-resistant depression: the first decade of progress. Cham: Springer Adis; 2016. p. 1–12.
   Google Scholar
• Trullas R, Skolnick P. Functional antagonists at the nmda receptor complex exhibit antidepressant actions. Eur J Pharmacol. 1990;185(1):1–10.
   PubMed Web of Science ®Google Scholar
• Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 47(4): 351–354. 2000. 10.1016/S0006-3223(99)00230-9.
   PubMed Web of Science ®Google Scholar
• Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an n-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 63(8): 856–864. 2006. 10.1001/archpsyc.63.8.856.
   PubMed Web of Science ®Google Scholar
• Wilkinson ST, Ballard ED, Bloch MH, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018;175(2):150–158. DOI:10.1176/appi.ajp.2017.17040472.
   PubMed Web of Science ®Google Scholar
• De Berardis D, Fornaro M, Valchera A, et al. Eradicating suicide at its roots: preclinical bases and clinical evidence of the efficacy of ketamine in the treatment of suicidal behaviors. Int J Mol Sci. 2018;19(10):2888. DOI:10.3390/ijms19102888.
   PubMed Web of Science ®Google Scholar
• Shiroma PR, Thuras P, Wels J, et al. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. Transl Psychiatry. 2020;10(1):1–9. DOI:10.1038/s41398-020-00897-0.
   PubMed Web of Science ®Google Scholar
• Fava M, Freeman MP, Flynn M, et al. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (trd). Mol Psychiatry. 2020;25(7):1592–1603. DOI:10.1038/s41380-018-0256-5.
   PubMed Web of Science ®Google Scholar
• Bahji A, Vazquez GH, Zarate CA Jr. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J Affect Disord. 2021;278:542–555.
   PubMed Web of Science ®Google Scholar
• Correia-Melo FS, Leal GC, Vieira F, et al. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. J Affect Disord. 2020;264:527–534.
   PubMed Web of Science ®Google Scholar
• Excellence N, Britain G. Guidance on the use of electroconvulsive therapy. London, United Kingdom: National Institute for Clinical Excellence London; 2003.
   Google Scholar
• Food and Drug Administration Department of Health and Human Services. Code of federal regulations title 21 - food and drugs chapter i - food and drug administration department of health and human services subchapter h - medical devices 2022 [cited 2022 February 26]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=882.5940
   Google Scholar
• McDonald WM, Weiner RD, Fochtmann LJ, et al. The fda and ect. J ECT. 2016;32(2):75. DOI:10.1097/YCT.0000000000000326.
   PubMed Web of Science ®Google Scholar
• Tørring N, Sanghani S, Petrides G, et al. The mortality rate of electroconvulsive therapy: a systematic review and pooled analysis. Acta Psychiatr Scand. 2017;135(5):388–397. DOI:10.1111/acps.12721.
   PubMed Web of Science ®Google Scholar
• Watts BV, Peltzman T, Shiner B. Mortality after electroconvulsive therapy. Br J Psychiatry. 2021;219(5):588–593. doi:10.1192/bjp.2021.63
   PubMed Web of Science ®Google Scholar
• Duma A, Maleczek M, Panjikaran B, et al. Major adverse cardiac events and mortality associated with electroconvulsive therapy: a systematic review and meta-analysis. Anesthesiology. 2019;130(1):83–91. DOI:10.1097/ALN.0000000000002488.
   PubMed Web of Science ®Google Scholar
• Østergaard SD, Kellner CH. Cardiac events after electroconvulsive therapy: comment. Anesthesiology. 2019;131(4):940–942.
   PubMed Web of Science ®Google Scholar
• Munk-Olsen T, Laursen TM, Videbech P, et al. All-cause mortality among recipients of electroconvulsive therapy: register-based cohort study. Br J Psychiatry. 2007;190(5):435–439. DOI:10.1192/bjp.bp.106.026740.
   PubMedGoogle Scholar
• Dominiak M, Antosik-Wójcińska AZ, Goetz Z, et al. Efficacy, safety and tolerability of formula-based unilateral vs bilateral electroconvulsive therapy in the treatment of major depression: a randomized open label controlled trial. J Psychiatr Res. 2021;133:52–59.
   PubMed Web of Science ®Google Scholar
• Darke S, Duflou J, Farrell M, et al. Characteristics and circumstances of death related to the self‐administration of ketamine. Addiction. 2021;116(2):339–345. DOI:10.1111/add.15154.
   PubMed Web of Science ®Google Scholar
• Schauer SG, April MD, Aden JK 3rd, et al. Impact of continuous ketamine infusion versus alternative regimens on mortality among burn intensive care unit patients: implications for prolonged field care. J Spec Oper Med. 2019;19(2):77–80.
   PubMedGoogle Scholar
• Park S, Choi AY, Park E, et al. Effects of continuous ketamine infusion on hemodynamics and mortality in critically ill children. PLoS One. 2019;14(10):e0224035. DOI:10.1371/journal.pone.0224035.
   PubMed Web of Science ®Google Scholar
• Swainson J, McGirr A, Blier P, et al. The Canadian network for mood and anxiety treatments (canmat) task force recommendations for the use of racemic ketamine in adults with major depressive disorder: recommandations du groupe de travail du réseau canadien pour les traitements de l’humeur et de l’anxiété (canmat) concernant l’utilisation de la kétamine racémique chez les adultes souffrant de trouble dépressif majeur. Can J Psychiatry. 2021;66(2):113–125. DOI:10.1177/0706743720970860.
   PubMed Web of Science ®Google Scholar
• Szarmach J, Cubała WJ, Włodarczyk A, et al. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety. Psychiatr Danub. 2019;31(suppl 3):585–590.
   PubMedGoogle Scholar
• Ceban F, Rosenblat JD, Kratiuk K, et al. Prevention and management of common adverse effects of ketamine and esketamine in patients with mood disorders. CNS Drugs. 2021;35(9):925–934. DOI:10.1007/s40263-021-00846-5.
   PubMed Web of Science ®Google Scholar
• Riva-Posse P, Reiff CM, Edwards JA, et al. Blood pressure safety of subanesthetic ketamine for depression: a report on 684 infusions. J Affect Disord. 2018;236:291–297.
   PubMed Web of Science ®Google Scholar
• Rodrigues NB, McIntyre RS, Lipsitz O, et al. Safety and tolerability of iv ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence. Expert Opin Drug Saf. 2020;19(8):1031–1040. DOI:10.1080/14740338.2020.1776699.
   PubMed Web of Science ®Google Scholar
• Hayase T, Yamamoto Y, Yamamoto K. Behavioral effects of ketamine and toxic interactions with psychostimulants. BMC Neurosci. 2006;7(1):1–10.
   PubMedGoogle Scholar
• Feifel D, Dadiomov D, Lee K C. Safety of repeated administration of parenteral ketamine for depression. Pharmaceuticals. 2020;13(7):151. DOI:10.3390/ph13070151.
   Web of Science ®Google Scholar
• Inc J Spravato® prescribing information. 2021 [October 31 2021].**Prescribing information provided by ketamine intranasal spray manafacturer outlining contraindications, possible side effects, administration instructions, clinical pharmacology information, use in specific populations, and other prescribing information.
   Google Scholar
• Winstock AR, Mitcheson L, Gillatt DA, et al. The prevalence and natural history of urinary symptoms among recreational ketamine users. BJU Int. 2012;110(11):1762–1766. DOI:10.1111/j.1464-410X.2012.11028.x.
   PubMed Web of Science ®Google Scholar
• Dadiomov D, Lee K. The effects of ketamine on suicidality across various formulations and study settings. Mental Health Clinician. 2019;9(1):48–60.
   PubMedGoogle Scholar
• Witt K, Potts J, Hubers A, et al. Ketamine for suicidal ideation in adults with psychiatric disorders: a systematic review and meta-analysis of treatment trials. Aust N Z J Psychiatry. 2020;54(1):29–45. DOI:10.1177/0004867419883341.
   PubMed Web of Science ®Google Scholar
• Xiong J, Lipsitz O, Chen-Li D, et al. The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: a systematic review and meta-analysis. J Psychiatr Res. 2021;134:57–68.
   PubMed Web of Science ®Google Scholar
• Ionescu DF, Bentley KH, Eikermann M, et al. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: a randomized, double blind, placebo controlled trial. J Affect Disord. 2019;243:516–524.
   PubMed Web of Science ®Google Scholar
• McInnes LA, Qian JJ, Gargeya RS, et al. A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings. J Affect Disord. 2022;301:486–495.
   PubMed Web of Science ®Google Scholar
• Phillips JL, Norris S, Talbot J, et al. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology. 2020;45(4):606–612. DOI:10.1038/s41386-019-0570-x.
   PubMed Web of Science ®Google Scholar
• Grunebaum MF, Galfalvy HC, Choo T-H, et al. Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial. Am J Psychiatry. 2018;175(4):327–335. DOI:10.1176/appi.ajp.2017.17060647.
   PubMed Web of Science ®Google Scholar
• Matveychuk D, Thomas RK, Swainson J, et al. Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. Ther Adv Psychopharmacol. 2020;10:2045125320916657.
   Web of Science ®Google Scholar
• Phillips JL, Jaworska N, Kamler E, et al. A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (can-bind) study protocol. BMC Psychiatry. 2020;20(1):1–11.
   PubMed Web of Science ®Google Scholar
• Administration USF, Drug. Fda approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic | fda 2019. [updated Tue, 03/05/201919:14. 2021. cited October 31] Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified
   Google Scholar
• Benson NM, Seiner SJ. Electroconvulsive therapy in children and adolescents: clinical indications and special considerations. Harv Rev Psychiatry. 2019;27(6):354–358.
   PubMed Web of Science ®Google Scholar
• MacQueen GM, Frey BN, Ismail Z, et al. Canadian network for mood and anxiety treatments (canmat) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations: youth, women, and the elderly. Can J Psychiatry. 2016;61(9):588–603.
   PubMed Web of Science ®Google Scholar
• Døssing E, Pagsberg AK. Electroconvulsive therapy in children and adolescents: a systematic review of current literature and guidelines. J ECT. 2021;37(3):158–170.
   PubMed Web of Science ®Google Scholar
• Ghaziuddin N, Kutcher SP, Knapp P. Practice parameter for use of electroconvulsive therapy with adolescents. J Am Acad Child Adolesc Psychiatry. 2004;43(12):1521–1539.
   PubMed Web of Science ®Google Scholar
• Lawton A, Moghraby OS. Depression in children and young people: identification and management in primary, community and secondary care (nice guideline cg28). Arch Dis Child Educ Pract. 2016;101(4):206–209.
   Google Scholar
• Health NIf, Care Excellence (UK). Guidance on the use of electroconvulsive therapy. 2021. Available from: https://www.nice.org.uk/guidance/ta59
   Google Scholar
• Wachtel LE, Dhossche DM, Kellner CH. When is electroconvulsive therapy appropriate for children and adolescents? Med Hypotheses. 2011;76(3):395–399.
   PubMed Web of Science ®Google Scholar
• Stein D, Weizman A, Bloch Y. Electroconvulsive therapy and transcranial magnetic stimulation: can they be considered valid modalities in the treatment of pediatric mood disorders? Child Adolesc Psychiatr Clin. 2006;15(4):1035–1056.
   PubMed Web of Science ®Google Scholar
• Ousdal OT, Argyelan M, Narr KL, et al. Brain changes induced by electroconvulsive therapy are broadly distributed. Biol Psychiatry. 2020;87(5):451–461. DOI:10.1016/j.biopsych.2019.07.010.
   PubMed Web of Science ®Google Scholar
• Kutcher S, Robertson HA. Electroconvulsive therapy in treatment-resistant bipolar youth. J Child Adolesc Psychopharmacol. 1995;5(3):167–175.
   Web of Science ®Google Scholar
• Hill MA, Courvoisie H, Dawkins K, et al. Ect for the treatment of intractable mania in two prepubertal male children. Convers Ther. 1997;13(2):74–82.
   PubMedGoogle Scholar
• Ghaziuddin N, Walter G. Electroconvulsive therapy in children and adolescents. Oxford (UK): Oxford University Press; 2013.
   Google Scholar
• Shoirah H, Hamoda HM. Electroconvulsive therapy in children and adolescents. Expert Rev Neurother. 2011;11(1):127–137.
   PubMed Web of Science ®Google Scholar
• Ghaziuddin N, King CA, Naylor MW, et al. Electroconvulsive treatment in adolescents with pharmacotherapy–refractory depression. J Child Adolesc Psychopharmacol. 6(4): 259–271. 1996. 10.1089/cap.1996.6.259.
   PubMed Web of Science ®Google Scholar
• Dolansky G, Shah A, Mosdossy G, et al. What is the evidence for the safety and efficacy of using ketamine in children? Paediatr Child Health. 2008;13(4):307–308. DOI:10.1093/pch/13.4.307.
   PubMed Web of Science ®Google Scholar
• Roelofse JA. The evolution of ketamine applications in children. Pediatr Anesthesia. 2010;20(3):240–245.
   PubMed Web of Science ®Google Scholar
• Di Vincenzo JD, Siegel A, Lipsitz O, et al. The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: a systematic review. J Psychiatr Res. 2021;137:232–241.
   PubMed Web of Science ®Google Scholar
• Dwyer JB, Landeros-Weisenberger A, Johnson JA, et al. Efficacy of intravenous ketamine in adolescent treatment-resistant depression: a randomized midazolam-controlled trial. Am J Psychiatry. 2021;178(4):352–362. DOI:10.1176/appi.ajp.2020.20010018.
   PubMed Web of Science ®Google Scholar
• Zimmermann KS, Richardson R, Baker KD. Esketamine as a treatment for paediatric depression: questions of safety and efficacy. Lancet Psychiatry. 2020;7(10):827–829.
   PubMed Web of Science ®Google Scholar
• Thomases DR, Cass DK, Tseng KY. Periadolescent exposure to the nmda receptor antagonist mk-801 impairs the functional maturation of local gabaergic circuits in the adult prefrontal cortex. J Neurosci. 2013;33(1):26–34.
   PubMed Web of Science ®Google Scholar
• Pérez MÁ, Morales C, Santander O, et al. Ketamine-treatment during late adolescence impairs inhibitory synaptic transmission in the prefrontal cortex and working memory in adult rats. Front Cell Neurosci. 2019;13:372.
   PubMed Web of Science ®Google Scholar
• Tan Y, Fujita Y, Pu Y, et al. Repeated intermittent administration of (r)-ketamine during juvenile and adolescent stages prevents schizophrenia-relevant phenotypes in adult offspring after maternal immune activation: a role of trkb signaling. Eur Arch Psychiatry Clin Neurosci. 2022;272(1):1–9. DOI:10.1007/s00406-021-01378-1.
   PubMedGoogle Scholar
• Kim S, Rush BS, Rice TR. A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders. Eur Child Adolesc Psychiatry. 2020;29(1):1–17.
   PubMedGoogle Scholar
• Gelenberg A, Freeman M, Markowitz J, et al. American psychiatric association practice guideline for the treatment of patients with major depressive disorder. Am J Psychiatry. 2010;167(Suppl 10):9–118.
   Google Scholar
• Rasmussen K. The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging. J ECT. 2002;18(1):58–59.
   PubMed Web of Science ®Google Scholar
• Jaffe R The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging (a task force report of the American psychiatric association). American Psychiatric Press; 2008.
   Google Scholar
• Coshal S, Jones K, Coverdale J, et al. An overview of reviews on the safety of electroconvulsive therapy administered during pregnancy. J Affective Disord Rep. 2019;25(1):2–6. DOI:10.1097/PRA.0000000000000359.
   Google Scholar
• Leiknes KA, Cooke MJ, Jarosch-von Schweder L, et al. Electroconvulsive therapy during pregnancy: a systematic review of case studies. Arch Women’s Mental Health. 2015;18(1):1–39. DOI:10.1007/s00737-013-0389-0.
   PubMed Web of Science ®Google Scholar
• Miller LJ. Use of electroconvulsive therapy during pregnancy. Psychiatr Serv. 1994;45(5):444–450.
   Google Scholar
• Calaway K, Coshal S, Jones K, et al. A systematic review of the safety of electroconvulsive therapy use during the first trimester of pregnancy. J ECT. 2016;32(4):230–235. DOI:10.1097/YCT.0000000000000330.
   PubMed Web of Science ®Google Scholar
• Li X, Guo C, Li Y, et al. Ketamine administered pregnant rats impair learning and memory in offspring via the creb pathway. Oncotarget. 2017;8(20):32433. DOI:10.18632/oncotarget.15405.
   PubMedGoogle Scholar
• Zhao T, Li Y, Wei W, et al. Ketamine administered to pregnant rats in the second trimester causes long-lasting behavioral disorders in offspring. Neurobiol Dis. 2014;68:145–155.
   PubMed Web of Science ®Google Scholar
• Burke TF, Mantena S, Opondo K, et al. A ketamine package for use in emergency cesarean delivery when no anesthetist is available: an analysis of 401 consecutive operations. Int J Gynecol Obstet. 2021. DOI:10.1002/ijgo.13965.
   Web of Science ®Google Scholar
• Riva-Posse P, Hermida AP, McDonald WM. The role of electroconvulsive and neuromodulation therapies in the treatment of geriatric depression. Psychiatr Clin. 2013;36(4):607–630.
   Google Scholar
• van Rooij Sj, Riva-Posse P, McDonald WM, et al. The efficacy and safety of neuromodulation treatments in late-life depression. Curr Treat Options Psychiatry. 2020;7(3):337–348.
   PubMedGoogle Scholar
• Tielkes CEM, Comijs HC, Verwijk E, et al. The effects of ect on cognitive functioning in the elderly: a review. Int J Geriatr Psychiatry. 2008;23(8):789–795. DOI:10.1002/gps.1989.
   PubMed Web of Science ®Google Scholar
• Dominiak M, Goetz Z, Antosik‐Wojcinska AZ, et al. Right unilateral versus bilateral formula‐based electroconvulsive therapy in the treatment of major depression in elderly patients: a randomised, open label, pilot controlled trial. Psychogeriatrics. 2021;21(2):175–184. DOI:10.1111/psyg.12652.
   PubMed Web of Science ®Google Scholar
• Antosik-Wójcińska A, Święcicki Ł. The efficacy and safety of ect in population before and after 60 years of age. Psychiatr Pol. 2016;50(5):1015–1026.
   PubMed Web of Science ®Google Scholar
• Mehdi SMA, Devanand D. Electroconvulsive Therapy in Elderly Patients With Cerebral Aneurysms: A Systematic Review With Clinical Recommendations. J Geriatr Psychiatry Neurol. 2021;34(6):504–512.
   PubMed Web of Science ®Google Scholar
• Ekstrand J, Fattah C, Persson M, et al. Racemic ketamine as an alternative to electroconvulsive therapy for unipolar depression: a randomized, open-label, non-inferiority Trial (KetECT). Int J Neuropsychopharmacol. 2021. DOI:10.1093/ijnp/pyab088
   Web of Science ®Google Scholar
• Zou L, Min S, Chen Q, et al. Subanesthetic dose of ketamine for the antidepressant effects and the associated cognitive impairments of electroconvulsive therapy in elderly patients—a randomized, double‐blind, controlled clinical study. Brain Behav. 2021;11(1):e01775. DOI:10.1002/brb3.1775.
   PubMed Web of Science ®Google Scholar
• Kokane SS, Armant RJ, Bolaños-Guzmán CA, et al. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant. Behav Brain Res. 2020;384:112548.
   PubMed Web of Science ®Google Scholar
• De Gregorio D, Aguilar-Valles A, Preller KH, et al. Hallucinogens in mental health: preclinical and clinical studies on lsd, psilocybin, mdma, and ketamine. J Neurosci. 2021;41(5):891–900. DOI:10.1523/JNEUROSCI.1659-20.2020.
   PubMed Web of Science ®Google Scholar
• Siegel RK. Phencyclidine and ketamine intoxication: a study of four populations of recreational users. NIDA Res Monogr. 1978;21(21):119–147.
   Google Scholar
• Jansen KLR. A review of the nonmedical use of ketamine: use, users and consequences. J Psychoactive Drugs. 2000;32(4):419–433.
   PubMed Web of Science ®Google Scholar
• Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA psychiatry. 74(4): 399–405. 2017. 10.1001/jamapsychiatry.2017.0080.
   PubMed Web of Science ®Google Scholar
• Muetzelfeldt L, Kamboj S, Rees H, et al. Journey through the k-hole: phenomenological aspects of ketamine use. Drug Alcohol Depend. 2008;95(3):219–229. DOI:10.1016/j.drugalcdep.2008.01.024.
   PubMed Web of Science ®Google Scholar
• Morgan C, Rees H, Curran HV. Attentional bias to incentive stimuli in frequent ketamine users. Psychol Med. 2008;38(9):1331–1340.
   PubMed Web of Science ®Google Scholar
• Brenner P, Brandt L, Li G, et al. Substance use disorders and risk for treatment resistant depression: a population‐based, nested case‐control study. Addiction. 2020;115(4):768–777. DOI:10.1111/add.14866.
   PubMed Web of Science ®Google Scholar
• Schak KM, Vande Voort JL, Johnson EK, et al. Potential risks of poorly monitored ketamine use in depression treatment. Am J Psychiatry. 2016;173(3):215–218. DOI:10.1176/appi.ajp.2015.15081082.
   PubMed Web of Science ®Google Scholar
• Liu JX, Zerbo E, Ross S. Intensive ketamine use for multiple years: a case report. Am J Addict. 2015;24(1):7–9.
   PubMed Web of Science ®Google Scholar
• Bobo WV, Vande Voort JL, Croarkin PE, et al. Ketamine for treatment‐resistant unipolar and bipolar major depression: critical review and implications for clinical practice. Depress Anxiety. 2016;33(8):698–710. DOI:10.1002/da.22505.
   PubMed Web of Science ®Google Scholar
• Wan L-B, Levitch CF, Perez AM, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry. 2014;76(3):10121.
   Web of Science ®Google Scholar
• Acevedo-Diaz EE, Cavanaugh GW, Greenstein D, et al. Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. J Affect Disord. 2020;263:568–575.
   PubMed Web of Science ®Google Scholar
• Perry EB, Cramer JA, Cho H-S, et al. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology (Berl). 2007;192(2):253–260. DOI:10.1007/s00213-007-0706-2.
   PubMed Web of Science ®Google Scholar
• Yoon G, Petrakis IL, Krystal JH. Association of combined naltrexone and ketamine with depressive symptoms in a case series of patients with depression and alcohol use disorder. JAMA psychiatry. 2019;76(3):337–338.
   PubMed Web of Science ®Google Scholar
• Dakwar E, Nunes EV, Hart CL, et al. A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: a randomized clinical trial. Am J Psychiatry. 2019;176(11):923–930. DOI:10.1176/appi.ajp.2019.18101123.
   PubMed Web of Science ®Google Scholar
• Dakwar E, Levin F, Hart CL, et al. A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial. Am J Psychiatry. 2020;177(2):125–133. DOI:10.1176/appi.ajp.2019.19070684.
   PubMed Web of Science ®Google Scholar
• Strong CE, Kabbaj M. Neural mechanisms underlying the rewarding and therapeutic effects of ketamine as a treatment for alcohol use disorder. Front Behav Neurosci. 2020;14:225.
   Web of Science ®Google Scholar
• Petrides G, Tobias KG, Kellner CH, et al. Continuation and maintenance electroconvulsive therapy for mood disorders: review of the literature. Neuropsychobiology. 2011;64(3):129–140. DOI:10.1159/000328943.
   PubMed Web of Science ®Google Scholar
• Kellner CH. Speed of response to ect. Psychiatr Times. 2010;27(5):12.
   Google Scholar
• Tor PC, Phu AH, Koh DS, et al. Electroconvulsive Therapy in a Time of Coronavirus Disease. The journal of ECT. 2020;36(2): 80–85. https://doi.org/10.1097/YCT.0000000000000690
   PubMed Web of Science ®Google Scholar
• Maixner DF, Weiner R, Reti IM, et al. Electroconvulsive therapy is an essential procedure. Am J Psychiatry. 2021;178(5):381–382. DOI:10.1176/appi.ajp.2020.20111647.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan VS, Kim YK, Yung W, et al. Ect in the time of the covid-19 pandemic. Australas Psychiatry. 2020;28(5):527–529. DOI:10.1177/1039856220953705.
   PubMed Web of Science ®Google Scholar
• Lambrichts S, Vansteelandt K, Crauwels B, et al. Relapse after abrupt discontinuation of maintenance electroconvulsive therapy during the covid‐19 pandemic. Acta Psychiatr Scand. 2021;144(3):230–237. DOI:10.1111/acps.13334.
   PubMed Web of Science ®Google Scholar
• Demchenko I, Blumberger DM, Flint AJ, et al. Electroconvulsive therapy in Canada during the first wave of covid-19: results of the “what happened” national survey. J ECT. 2021;38(1): 52–59. https://doi.org/10.1097/YCT.0000000000000801
   Web of Science ®Google Scholar
• Inc J Spravato® (esketamine) patient enrolment form 2021 [cited 2021 31 October]. Available from: https://www.spravatorems.com/pdfs/SPRAVATO_REMS_Patient_Enrollment_Form
   Google Scholar
• Inc. J. Spravato® rems program overview (risk evaluation and mitigation strategy) 2021 [cited 2021 October 31]; This overview describes the SPRAVATO® REMS requirements and responsibilities of inpatient healthcare settings, outpatient healthcare settings, pharmacies, and patients.]. Available from: https://www.spravatorems.com/pdfs/REMSProgramOverview ** Risk Evaluation and Mitigation Strategy (REMS) restrictions imposed for esketamine distribution, monitoring, and implementation.
   Google Scholar
• McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 178(5): 383–399. 2021. 10.1176/appi.ajp.2020.20081251.
   PubMed Web of Science ®Google Scholar
• Singh JB, Fedgchin M, Daly EJ, et al. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants. In Advances in pharmacology. Vol. 89. London,United Kingdom: Elsevier; 2020. p. 237–259.
   Google Scholar
• Wajs E, Aluisio L, Holder R, et al. Esketamine nasal spray plus oral antidepressant in patients with treatment-resistant depression: assessment of long-term safety in a phase 3, open-label study (sustain-2). J Clin Psychiatry. 2020;81(3).
   PubMed Web of Science ®Google Scholar
• Medicare. Does medicare cover esketamine? 2021. [cited November 11]. Available from: https://www.medicare.org/articles/does-medicare-cover-esketamine/
   Google Scholar
• Amato E. Abstract outcomes of ketamine iv treatments for tms therapy poor responders. Brain Stimul. 2020;13(6):1846–1847.
   Google Scholar
• Bahr R, Lopez A, Rey JA. Intranasal esketamine (spravatotm) for use in treatment-resistant depression in conjunction with an oral antidepressant. Pharm Ther. 2019;44(6):340.
   Google Scholar
• Centers KW Cost of ketamine infusion treatments. 2021. [cited 2021 October 31]. Available from: https://www.ketaminewellnesscenters.com/treatment-cost/
   Google Scholar
• Bozymski KM, Crouse EL, Titus-Lay EN, et al. Esketamine: a novel option for treatment-resistant depression. Ann Pharmacother. 2020;54(6):567–576. DOI:10.1177/1060028019892644.
   PubMed Web of Science ®Google Scholar
• Review. IfCaE. Esketamine for the treatment of treatment-resistant depression: effec- tiveness and value. 2021. [cited November 11]. Available from: https://icer-review.org/wp-content/uploads/2018/10/ICER_TRD_Evidence_Report_050919.pdf
   Google Scholar
• Hallford DJ, Rusanov D, Yeow J, et al. Overgeneral and specific autobiographical memory predict the course of depression: an updated meta-analysis. Psychol Med. 2021;51(6):909–926. DOI:10.1017/S0033291721001343.
   PubMed Web of Science ®Google Scholar
• Semkovska M, Quinlivan L, O’Grady T, et al. Cognitive function following a major depressive episode: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(10):851–861. DOI:10.1016/S2215-0366(19)30291-3.
   PubMed Web of Science ®Google Scholar
• Rock PL, Roiser J, Riedel WJ, et al. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44(10):2029–2040. DOI:10.1017/S0033291713002535.
   PubMed Web of Science ®Google Scholar
• Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biol Psychiatry. 2010;68(6):568–577.
   PubMed Web of Science ®Google Scholar
• Bodnar A, Krzywotulski M, Lewandowska A, et al. Electroconvulsive therapy and cognitive functions in treatment-resistant depression. World J Biol Psychiatry. 2016;17(2):159–164. DOI:10.3109/15622975.2015.1091501.
   PubMed Web of Science ®Google Scholar
• Obbels J, Vansteelandt K, Verwijk E, et al. Mmse changes during and after ect in late-life depression: a prospective study. Am J Geriatric Psychiatry. 2019;27(9):934–944. DOI:10.1016/j.jagp.2019.04.006.
   PubMed Web of Science ®Google Scholar
• Mohn C, Rund BR. Neurognitive function and symptom remission 2 years after ect in major depressive disorders. J Affect Disord. 2019;246:368–375.
   PubMed Web of Science ®Google Scholar
• Donahue AB. Electroconvulsive therapy and memory loss: a personal journey. J ECT. 2000;16(2):133–143.
   PubMed Web of Science ®Google Scholar
• Griffiths C, O’Neill-Kerr A. Patients’, carers’, and the public’s perspectives on electroconvulsive therapy. Front Psychiatry. 2019;10:304.
   PubMed Web of Science ®Google Scholar
• Verwijk E, Obbels J, Spaans H, et al. Doctor, will i get my memory back? Electroconvulsive therapy and cognitive side-effects in daily practice. Tijdschr Psychiatr. 2017;59(10):632–637.
   PubMedGoogle Scholar
• Sigström R, Nordenskjöld A, Juréus A, et al. Long-term subjective memory after electroconvulsive therapy. BJPsych Open. 2020;6(2). DOI:10.1192/bjo.2020.9.
   PubMed Web of Science ®Google Scholar
• Bassa A, Sagués T, Porta-Casteràs D, et al. The neurobiological basis of cognitive side effects of electroconvulsive therapy: a systematic review. Brain Sci. 2021;11(10):1273. DOI:10.3390/brainsci11101273.
   PubMed Web of Science ®Google Scholar
• Sackeim HA, Prudic J, Fuller R, et al. The cognitive effects of electroconvulsive therapy in community settings. Neuropsychopharmacology. 2007;32(1):244–254. DOI:10.1038/sj.npp.1301180.
   PubMed Web of Science ®Google Scholar
• Rybakowski JK, Permoda-Osip A, Bartkowska-Sniatkowska AK. Its safety, tolerability, and impact on neurocognition. Ketamine for treatment-resistant depression. Adis Cham, Switzerland: Springer International Publishing; 2016. p. 57–71.
   Google Scholar
• Bokor G, Anderson PD. Ketamine: an update on its abuse. J Pharm Pract. 2014;27(6):582–586.
   PubMedGoogle Scholar
• Veraart JK, Smith-Apeldoorn SY, Spaans H-P, et al. Is ketamine an appropriate alternative to ECT for patients with treatment resistant depression? A systematic review. J Affect Disord. 2020;281:82–89.
   PubMed Web of Science ®Google Scholar
• Basso L, Bönke L, Aust S, et al. Antidepressant and neurocognitive effects of serial ketamine administration versus ect in depressed patients. J Psychiatr Res. 2020;123:1–8.
   PubMed Web of Science ®Google Scholar
• Souza-Marques B, Santos-Lima C, Araújo-de-freitas L, et al. Neurocognitive effects of ketamine and esketamine for treatment-resistant major depressive disorder: a systematic review. Harv Rev Psychiatry. 29(5): 340–350. 2021. 10.1097/HRP.0000000000000312.
   PubMed Web of Science ®Google Scholar
• Turken U, Whitfield-Gabrieli S, Bammer R, et al. Cognitive processing speed and the structure of white matter pathways: convergent evidence from normal variation and lesion studies. Neuroimage. 2008;42(2):1032–1044. DOI:10.1016/j.neuroimage.2008.03.057.
   PubMed Web of Science ®Google Scholar
• Sydnor VJ, Lyall AE, Cetin-Karayumak S, et al. Studying pre-treatment and ketamine-induced changes in white matter microstructure in the context of ketamine’s antidepressant effects. Transl Psychiatry. 2020;10(1):1–10. DOI:10.1038/s41398-020-01122-8.
   PubMed Web of Science ®Google Scholar
• Watkins E, Brown R. Rumination and executive function in depression: an experimental study. J Neurol Neurosurg Psychiatry. 2002;72(3):400–402.
   PubMed Web of Science ®Google Scholar
• Disner SG, Beevers CG, Haigh EA, et al. Neural mechanisms of the cognitive model of depression. Nat Rev Neurosci. 2011;12(8):467–477. DOI:10.1038/nrn3027.
   PubMed Web of Science ®Google Scholar
• Nikiforuk A, Popik P. Ketamine prevents stress-induced cognitive inflexibility in rats. Psychoneuroendocrinology. 2014;40:119–122.
   PubMed Web of Science ®Google Scholar
• Patton MS, Lodge DJ, Morilak DA, et al. Ketamine corrects stress-induced cognitive dysfunction through jak2/stat3 signaling in the orbitofrontal cortex. Neuropsychopharmacology. 2017;42(6):1220–1230. DOI:10.1038/npp.2016.236.
   PubMed Web of Science ®Google Scholar
• Li N, Lee B, Liu R-J, et al. Mtor-dependent synapse formation underlies the rapid antidepressant effects of nmda antagonists. Science. 2010;329(5994):959–964. DOI:10.1126/science.1190287.
   PubMed Web of Science ®Google Scholar
• Yang C, Y-M H, Zhou Z-Q, et al. Acute administration of ketamine in rats increases hippocampal bdnf and mtor levels during forced swimming test. Ups J Med Sci. 2013;118(1):3–8. DOI:10.3109/03009734.2012.724118.
   PubMed Web of Science ®Google Scholar
• Shiroma PR, Albott CS, Johns B, et al. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol. 2014;17(11):1805–1813. DOI:10.1017/S1461145714001011.
   PubMed Web of Science ®Google Scholar
• Murrough JW, Wan L-B, Iacoviello B, et al. Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. Psychopharmacology (Berl). 2014;231(3):481–488. DOI:10.1007/s00213-013-3255-x.
   Web of Science ®Google Scholar
• Murrough JW, Burdick KE, Levitch CF, et al. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology. 2015;40(5):1084–1090. DOI:10.1038/npp.2014.298.
   PubMed Web of Science ®Google Scholar
• Shiroma PR, Thuras P, Wels J, et al. Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord. 2020;277:470–477.
   PubMed Web of Science ®Google Scholar
• Obbels J, Verwijk E, Bouckaert F, et al. Ect-related anxiety: a systematic review. J ECT. 2017;33(4):229–236. DOI:10.1097/YCT.0000000000000383.
   PubMed Web of Science ®Google Scholar
• Gastaldon C, Raschi E, Kane JM, et al. Post-marketing safety concerns with esketamine: a disproportionality analysis of spontaneous reports submitted to the fda adverse event reporting system. Psychother Psychosom. 2021;90(1):41–48. DOI:10.1159/000510703.
   PubMed Web of Science ®Google Scholar
• Gastaldon C, Papola D, Ostuzzi G, et al. Esketamine for treatment resistant depression: a trick of smoke and mirrors? Epidemiol Psychiatr Sci. 2020;29. DOI:10.1017/S2045796019000751.
   Web of Science ®Google Scholar
• Singh JB, Fedgchin M, Daly EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173(8):816–826. DOI:10.1176/appi.ajp.2016.16010037.
   PubMed Web of Science ®Google Scholar
• Luckenbaugh DA, Niciu MJ, Ionescu DF, et al. Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord. 2014;159:56–61.
   PubMed Web of Science ®Google Scholar
• Niciu MJ, Shovestul BJ, Jaso BA, et al. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. J Affect Disord. 2018;232:310–315.
   PubMed Web of Science ®Google Scholar
• Ballard ED, Zarate CA. The role of dissociation in ketamine’s antidepressant effects. Nat Commun. 2020;11(1):1–7.
   PubMed Web of Science ®Google Scholar
• Krech L, Belz M, Besse M, et al. Influence of depressed patients’ expectations prior to electroconvulsive therapy on its effectiveness and tolerability (exp-ect): a prospective study. Eur Arch Psychiatry Clin Neurosci. 2018;268(8):809–817. DOI:10.1007/s00406-017-0840-8.
   PubMed Web of Science ®Google Scholar
• Sienaert P. Based on a true story? The portrayal of ect in international movies and television programs. Brain Stimul. 2016;9(6):882–891.
   PubMed Web of Science ®Google Scholar
• Tsai J, Huang M, He H, et al. Cross-cultural comparison of perceptions and knowledge about electroconvulsive therapy among adults who screened positive for depression in the United States, India, and China. J ECT. 2021;37(4):274–280. DOI:10.1097/YCT.0000000000000775.
   PubMed Web of Science ®Google Scholar
• Tsai J, Huang M, Wilkinson ST, et al. Effects of video psychoeducation on perceptions and knowledge about electroconvulsive therapy. Psychiatry Res. 2020;286:112844.
   PubMed Web of Science ®Google Scholar
• Griffiths C, Thompson R Patient reported experience of electroconvulsive therapy (ect). 2018.
   Google Scholar
• Brown SK, Nowlin RB, Sartorelli R, et al. Patient experience of electroconvulsive therapy: a retrospective review of clinical outcomes and satisfaction. J ECT. 2018;34(4):240–246. DOI:10.1097/YCT.0000000000000492.
   PubMed Web of Science ®Google Scholar
• Zhang MW, Hong YX, Husain SF, et al. Analysis of print news media framing of ketamine treatment in the United States and Canada from 2000 to 2015. PLoS One. 2017;12(3):e0173202. DOI:10.1371/journal.pone.0173202.
   PubMed Web of Science ®Google Scholar
• Palamar JJ, Le A. Media coverage about medical benefits of mdma and ketamine affects perceived likelihood of engaging in recreational use. Addict Res Theory. 2021;1–8. DOI:10.1080/16066359.2021.1940972
   Web of Science ®Google Scholar
• Jilka S, Odoi CM, Wilson E, et al. Ketamine treatment for depression: qualitative study exploring patient views. BJPsych Open. 2021;7(1). DOI:10.1192/bjo.2020.165.
   PubMed Web of Science ®Google Scholar
• Jilka S, Murray C, Wieczorek A, et al. Exploring patients’ and carers’ views about the clinical use of ketamine to inform policy and practical decisions: mixed-methods study. BJPsych Open. 2019;5(5). DOI:10.1192/bjo.2019.52.
   PubMedGoogle Scholar
• Earleywine M, Altman BR, De Leo J. Cognitive behavioral therapy, ketamine, and combination treatment for depression: impressions of credibility in participants with self-reported depressive symptoms. J Psychoactive Drugs. 2021;1–11. DOI:10.1080/02791072.2021.1912863
   Web of Science ®Google Scholar
• Constantino MJ, Coyne AE, Boswell JF, et al. A meta-analysis of the association between patients’ early perception of treatment credibility and their posttreatment outcomes. Psychotherapy. 2018;55(4):486. DOI:10.1037/pst0000168.
   PubMed Web of Science ®Google Scholar
• Griffiths C, Walker K, Reid I, et al. A qualitative study of patients’ experience of ketamine treatment for depression: the ‘ketamine and me’project. J Affective Disord Rep. 2021;4:100079.
   Google Scholar
• Chaves TV, Wilffert B, Sanchez ZM. The use of ketamine to cope with depression and post-traumatic stress disorder: a qualitative analysis of the discourses posted on a popular online forum. Am J Drug Alcohol Abuse. 2020;46(5):613–624.
   PubMed Web of Science ®Google Scholar
• Lascelles K, Marzano L, Brand F, et al. Ketamine treatment for individuals with treatment-resistant depression: longitudinal qualitative interview study of patient experiences. BJPsych Open. 2021;7(1). DOI:10.1192/bjo.2020.132.
   Web of Science ®Google Scholar
• Ross EL, Zivin K, Maixner DF. Cost-effectiveness of electroconvulsive therapy vs pharmacotherapy/psychotherapy for treatment-resistant depression in the United States. JAMA psychiatry. 2018;75(7):713–722.
   PubMed Web of Science ®Google Scholar
• Slade EP, Jahn DR, Regenold WT, et al. Association of electroconvulsive therapy with psychiatric readmissions in us hospitals. JAMA psychiatry. 2017;74(8):798–804. DOI:10.1001/jamapsychiatry.2017.1378.
   PubMed Web of Science ®Google Scholar
• Rhee TG, Sint K, Olfson M, et al. Association of ECT with risks of all-cause mortality and suicide in older medicare patients. Am J Psychiatry. 2021;178(12):1089–1097. DOI:10.1176/appi.ajp.2021.21040351.
   PubMed Web of Science ®Google Scholar
• Sforzini L, Worrell C, Kose M, et al. A delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. Mol Psychiatry. 2021;1–14. https://www.nature.com/articles/s41380-021-01381-x.pdf
   PubMed Web of Science ®Google Scholar
• Mathew SJ, Wilkinson ST, Altinay M, et al. Electroconvulsive therapy (ECT) vs. Ketamine in patients with treatment-resistant depression: the Elekt-D study protocol. Contemp Clin Trials. 2019;77:19–26. DOI:10.1016/j.cct.2018.12.009.
   PubMed Web of Science ®Google Scholar
• Brown ES, Murray M, Carmody TJ, et al. The quick inventory of depressive symptomatology-self-report: a psychometric evaluation in patients with asthma and major depressive disorder. Ann Allergy Asthma Immunol. 2008;100(5):433–438. DOI:10.1016/S1081-1206(10)60467-X.
   PubMed Web of Science ®Google Scholar
• Sackeim HA, Dibué M, Bunker MT, et al. The long and winding road of vagus nerve stimulation: challenges in developing an intervention for difficult-to-treat mood disorders. Neuropsychiatr Dis Treat. 2020;16:3081.
   PubMed Web of Science ®Google Scholar
• Daskalakis ZJ, McClintock SM, Hadas I, et al. Confirmatory efficacy and safety trial of magnetic seizure therapy for depression (crest-mst): protocol for identification of novel biomarkers via neurophysiology. Trials. 2021;22(1):1–8. DOI:10.1186/s13063-020-04976-x.
   PubMed Web of Science ®Google Scholar
• Cole EJ, Phillips AL, Bentzley BS, et al. Stanford neuromodulation therapy (snt): a double-blind randomized controlled trial. Am J Psychiatry. 2021;179(2):132–141.
   PubMed Web of Science ®Google Scholar